Clinical trials with anti‐angiogenic agents in hematological malignancies
Open accessThe DOI matches its Crossref record; 107 of the 107 references it cites were found in a registry or an index.
Abstract
New blood vessel formation (angiogenesis) is not only essential for the growth of solid tumors but there is also emerging evidence that progression of hematological malignancies like multiple myeloma, acute leukemias, and myeloproliferative neoplasms, also depends on new blood vessel formation. Anti-angiogenic strategies have become an important therapeutic modality for solid tumors. Several anti-angiogenic agents targeting angiogenesis-related pathways like monoclonal antibodies, receptor tyrosine kinase inhibitors, immunomodulatory drugs, and proteasome inhibitors have been entered clinical trials or have been already approved for the treatment of hematological malignancies as well and in some instances these pathways have emerged as promising therapeutic targets. This review summarizes recent advances in the basic understanding of the role of angiogenesis in hematological malignancies and clinical trials with novel therapeutic approaches targeting angiogenesis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“ECs are targeted indirectly for tumor therapy by inhibiting angiogenesis via neutralizing antibodies for VEGF or inhibitors of VEGF activity [34].”
From Tumor microenvironment signaling and therapeutics in cancer progression (2023) · cites this paper as [34]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer
Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., Berlin, J., Baron, A., Griffing, S., Holmgren, E., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032691 · Cited by 10,968 · cited 1×
“Administration of bevacizumab, in combination with cytotoxic chemotherapy, conferred benefits to patients with metastatic colorectal cancer, non-squamous, non-small cell lung cancer and metastatic breast cancer [62-64].”
Tumor angiogenesis: therapeutic implications
Sherwood, L. M., Parris, E. E., & Folkman, J. (1971) · New England Journal of Medicine · doi:10.1056/nejm197111182852108 · Cited by 10,187 · cited 1×
“Based on a balance between angiogenic and anti-angiogenic growth factors, a tumor of this size can stay dormant for a very long time period until the so-called angiogenic switch occurs [2].”
The biology of VEGF and its receptors
Ferrara, N., Gerber, H.-P., & LeCouter, J. (2003) · Nature Medicine · doi:10.1038/nm0603-669 · Cited by 9,591 · cited 3×
“Thus, VEGF and VEGFR represent significant anti-cancer therapy targets, which elegantly bypass potential tumor-related treatment barriers [4].”
InfluentialAngiogenesis in cancer, vascular, rheumatoid and other disease
Folkman, J. (1995) · Nature Medicine · doi:10.1038/nm0195-27 · Cited by 7,627 · cited 1×
“Introduction The hypothesis of tumor angiogenesis in malignancies was raised by Judah Folkman: To grow over a certain size of a few millimetres in diameter solid tumors need blood supply from surrounding vessel [1].”
Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis
Hanahan, D., & Folkman, J. (1996) · Cell · doi:10.1016/s0092-8674(00)80108-7 · Cited by 6,885
Sunitinib versus Interferon Alfa in Metastatic Renal-Cell Carcinoma
Motzer, R. J., Hutson, T. E., Tomczak, P., Michaelson, M. D., Bukowski, R. M., Rixe, O., Oudard, S., Negrier, S., Szczylik, C., Kim, S. T., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa065044 · Cited by 5,775 · cited 1×
“Additionally, two small-molecule inhibitors targeting VEGFRs and other kinases, sorafenib (NexavarTM, Bayer and Onyx pharmaceuticals) and sunitinib (SutentTM, Pfizer), have been approved based on their efficacy in treating renal cell- and hepatocellular carcinoma [65,66].”
Paclitaxel–Carboplatin Alone or with Bevacizumab for Non–Small-Cell Lung Cancer
Sandler, A., Gray, R., Perry, M. C., Brahmer, J., Schiller, J. H., Dowlati, A., Lilenbaum, R., & Johnson, D. H. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa061884 · Cited by 5,761 · cited 1×
“Administration of bevacizumab, in combination with cytotoxic chemotherapy, conferred benefits to patients with metastatic colorectal cancer, non-squamous, non-small cell lung cancer and metastatic breast cancer [ 62-64 ].”
Vascular Endothelial Growth Factor Is a Secreted Angiogenic Mitogen
Leung, D. W., Cachianes, G., Kuang, W.-J., Goeddel, D. V., & Ferrara, N. (1989) · Science · doi:10.1126/science.2479986 · Cited by 4,986 · cited 1×
“The role for VEGF in hematogical malignancies has been extensively studied since its isolation from the leukemia cell line HL- 60 in 1989 [25].”
Sorafenib in Advanced Clear-Cell Renal-Cell Carcinoma
Escudier, B., Eisen, T., Stadler, W. M., Szczylik, C., Oudard, S., Siebels, M., Negrier, S., Chevreau, C., Solska, E., Desai, A. A., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa060655 · Cited by 4,802 · cited 1×
“Additionally, two small-molecule inhibitors targeting VEGFRs and other kinases, sorafenib (Nexavar™, Bayer and Onyx pharmaceuticals) and sunitinib (Sutent™, Pfizer), have been approved based on their efficacy in treating renal cell- and hepatocellular carcinoma [ 65 ,66].”
A Gain-of-Function Mutation of JAK2 in Myeloproliferative Disorders
Kralovics, R., Passamonti, F., Buser, A. S., Teo, S.-S., Tiedt, R., Passweg, J. R., Tichelli, A., Cazzola, M., & Skoda, R. C. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051113 · Cited by 3,470 · cited 1×
“The identification of an acquired somatic mutation in the JAK2 gene, resulting in a valine to phenylalanine substitution at position 617 (JAK2-V617F), has provided new insights into the pathogenesis of BCR-ABL1-negative MPN, being present in most patients with polycythaemia vera (PV) and in about 50% of patients with…”
Paclitaxel plus Bevacizumab versus Paclitaxel Alone for Metastatic Breast Cancer
Miller, K., Wang, M., Gralow, J., Dickler, M., Cobleigh, M., Perez, E. A., Shenkier, T., Cella, D., & Davidson, N. E. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa072113 · Cited by 3,081 · cited 1×
“Administration of bevacizumab, in combination with cytotoxic chemotherapy, conferred benefits to patients with metastatic colorectal cancer, non-squamous, non-small cell lung cancer and metastatic breast cancer [62-64].”
Activating Mutations of NOTCH1 in Human T Cell Acute Lymphoblastic Leukemia
Weng, A. P., Ferrando, A. A., Lee, W., Morris, J. P., Silverman, L. B., Sanchez-Irizarry, C., Blacklow, S. C., Look, A. T., & Aster, J. C. (2004) · Science · doi:10.1126/science.1102160 · Cited by 2,715 · cited 2×
“Activating Notch-mutations have been shown to be present in at least 50% of human T-cell acute lymphoblastic leukaemia (T-ALL) cases and have been proved to play a unifying role in the pathogenesis of TALL [30].”
Antitumor Activity of Thalidomide in Refractory Multiple Myeloma
Singhal, S., Mehta, J., Desikan, R., Ayers, D., Roberson, P., Eddlemon, P., Munshi, N., Anaissie, E., Wilson, C., Dhodapkar, M., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199911183412102 · Cited by 2,575 · cited 2×
“The 2-year event-free survival and overall survival were 20 and 48%, respectively [83,84].”
Thalidomide is an inhibitor of angiogenesis.
D'Amato, R. J., Loughnan, M. S., Flynn, E., & Folkman, J. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.9.4082 · Cited by 2,454
Lyden, D., Hattori, K., Dias, S., Costa, C., Blaikie, P., Butros, L., Chadburn, A., Heissig, B., Marks, W., Witte, L., et al. (2001) · Nature Medicine · doi:10.1038/nm1101-1194 · Cited by 1,860
Presta, L. G., Chen, H., O'Connor, S. J., Chisholm, V., Meng, Y. G., KRUMMEN, L. A., Winkler, M., & Ferrara, N. (1997) · PubMed · Cited by 1,608
Lenalidomide plus Dexamethasone for Relapsed or Refractory Multiple Myeloma
Dimopoulos, M., Spencer, A., Attal, M., Prince, H. M., Harousseau, J.-L., Dmoszynska, A., Miguel, J. S., Hellmann, A., Facon, T., Foà, R., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa070594 · Cited by 1,450 · cited 2×
“In 2 phase III trials lenalidomide in combination with dexamethasone, it showed remarkable response rates and better toxicity profile than thalidomide [96,97].”
Lenalidomide plus Dexamethasone for Relapsed Multiple Myeloma in North America
Weber, D. M., Chen, C., Niesvizky, R., Wang, M., Belch, A., Stadtmauer, E. A., Siegel, D., Borrello, I., Rajkumar, S. V., Chanan-Khan, A. A., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa070596 · Cited by 1,233 · cited 2×
“In 2 phase III trials lenalidomide in combination with dexamethasone, it showed remarkable response rates and better toxicity profile than thalidomide [96,97].”
Blockade of Dll4 inhibits tumour growth by promoting non-productive angiogenesis
Noguera-Troise, I., Daly, C., Papadopoulos, N. J., Coetzee, S., Boland, P., Gale, N. W., Chieh Lin, H., Yancopoulos, G. D., & Thurston, G. (2006) · Nature · doi:10.1038/nature05355 · Cited by 1,032 · cited 3×
“Further, certain xenografts that are resistant to anti-VEGF therapy are reported to be sensitive to anti-Dll4 and combination treatment with antiVEGF and anti-Dll4 has additive inhibitory effects on tumor growth [13-15].”
Inhibition of Dll4 signalling inhibits tumour growth by deregulating angiogenesis
Ridgway, J., Zhang, G., Wu, Y., Stawicki, S., Liang, W.-C., Chanthery, Y., Kowalski, J., Watts, R. J., Callahan, C., Kasman, I., et al. (2006) · Nature · doi:10.1038/nature05313 · Cited by 986 · cited 4×
“Further, certain xenografts that are resistant to anti-VEGF therapy are reported to be sensitive to anti-Dll4 and combination treatment with antiVEGF and anti-Dll4 has additive inhibitory effects on tumor growth [13-15].”
InfluentialRajkumar, S. V., Blood, E., Vesole, D., Fonseca, R., & Greipp, P. R. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.0221 · Cited by 865
Richardson, P. G., Weller, E., Lonial, S., Jakubowiak, A. J., Jagannath, S., Raje, N. S., Avigan, D. E., Xie, W., Ghobrial, I. M., Schlossman, R. L., et al. (2010) · Blood · doi:10.1182/blood-2010-02-268862 · Cited by 861 · cited 1×
“[104] the combination lenalidomide, bortezomib, and dexamethasone was evaluated in front-line myeloma.”
Wood, J. M., Bold, G., Buchdunger, E., Cozens, R. M., Ferrari, S. M., Frei, J., Hofmann, F., Mestan, J., Mett, H., O'Reilly, T., et al. (2000) · PubMed · Cited by 845
Gill, M., Dias, S., Hattori, K., Rivera, M. L., Hicklin, D., Witte, L., Girardi, L., Yurt, R., Himel, H., & Rafii, S. (2001) · Circulation Research · doi:10.1161/01.res.88.2.167 · Cited by 798 · cited 1×
“VEGFR-1 is also expressed on hematopoietic stem cells, vascular smooth muscle cells, monocytes, and leukemic cells [6,7], while VEGFR-2 is expressed on endothelial progenitor cells and megakaryocytes [8,9].”
Wedge, S. R., Kendrew, J., Hennequin, L. F., Valentine, P. J., Barry, S. T., Brave, S. R., Smith, N. R., James, N. H., Dukes, M., Curwen, J. O., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-4409 · Cited by 714 · cited 1×
“Cediranib (AZD2171, Recentin®) is a potent inhibitor of both VEGFR-1 and VEGFR-2; it also has activity against c-kit, PDGFR-β, and VEGFR-3 at nanomolar concentrations [80].”
Hattori, K., Dias, S., Heissig, B., Hackett, N. R., Lyden, D., Tateno, M., Hicklin, D. J., Zhu, Z., Witte, L., Crystal, R. G., et al. (2001) · The Journal of Experimental Medicine · doi:10.1084/jem.193.9.1005 · Cited by 687 · cited 1×
“VEGFR-1 is also expressed on hematopoietic stem cells, vascular smooth muscle cells, monocytes, and leukemic cells [6,7], while VEGFR-2 is expressed on endothelial progenitor cells and megakaryocytes [8,9].”
The Notch signaling pathway: Transcriptional regulation at Notch target genes
Borggrefe, T., & Oswald, F. (2009) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-009-8668-7 · Cited by 661 · cited 1×
“Regarding the Notch pathway, Notch signals are oncogenic in hematogical malignancies in many cellular contexts [29].”
Bone marrow angiogenesis and progression in multiple myeloma
Vacca, A., Ribatti, D., Roncali, L., Ranieri, G., Serio, G., Silvestris, F., & Dammacco, F. (1994) · British Journal of Haematology · doi:10.1111/j.1365-2141.1994.tb08304.x · Cited by 630
Analysis of Biological Effects and Signaling Properties of Flt-1 (VEGFR-1) and KDR (VEGFR-2)
Gille, H., Kowalski, J., Li, B., LeCouter, J., Moffat, B., Zioncheck, T. F., Pelletier, N., & Ferrara, N. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m002016200 · Cited by 620 · cited 1×
“VEGFR-1 (ligands include VEGF-A, -B and placental growth factor [PIGF]) and VEGFR-2 (ligands include VEGF-A, -C and -D) are predominantly expressed on vascular endothelial cells, and activation of VEGFR-2 appears to be both, necessary and sufficient, to mediate VEGF-dependent angiogenesis and induction of vascular per…”
Vacca, A., Ribatti, D., Presta, M., Minischetti, M., Iurlaro, M., Ria, R., Albini, A., Bussolino, F., & Dammacco, F. (1999) · Blood · doi:10.1182/blood.v93.9.3064 · Cited by 599
Expression of vascular endothelial growth factor and its receptors in hematopoietic malignancies.
Bellamy, W. T., Richter, L., Frutiger, Y. M., & Grogan, T. M. (1999) · PubMed · Cited by 559
Spectrum of tumor angiogenesis in the bone marrow of children with acute lymphoblastic leukemia.
Pérez‐Atayde, A. R., Sallan, S. E., Tedrow, U. B., Connors, S. L., Allred, E. N., & Folkman, J. (1997) · Europe PMC (PubMed Central) · Cited by 553
Gupta, D., Treon, S., Shima, Y., Hideshima, T., Podar, K., Tai, Y., Lin, B., Lentzsch, S., Davies, F., Chauhan, D., et al. (2001) · Leukemia · doi:10.1038/sj.leu.2402295 · Cited by 553 · cited 1×
“lenalidomide) have been shown to significantly decrease the expression of the pro-angiogenic factors VEGF and Interleukin-6 (IL-6) in MM [87].”
Barlogie, B., Desikan, R., Eddlemon, P., Spencer, T., Zeldis, J., Munshi, N., Badros, A., Zangari, M., Anaissie, E., Epstein, J., et al. (2001) · Blood · doi:10.1182/blood.v98.2.492 · Cited by 541 · cited 2×
“The 2-year event-free survival and overall survival were 20 and 48%, respectively [83,84].”
Majka, M., Janowska-Wieczorek, A., Ratajczak, J., Ehrenman, K., Pietrzkowski, Z., Kowalska, M. A., Gewirtz, A. M., Emerson, S. G., & Ratajczak, M. Z. (2001) · Blood · doi:10.1182/blood.v97.10.3075 · Cited by 508 · cited 1×
“The bone marrow tumor cells upregulates several factors, including interleukin-6, granulocyte-macrophage colony-stimulating factor and VEGF, have autocrine and paracrine effects acting on multiple cell types, thereby stimulating angiogenesis and leading to increased vascularity [7, 24 ].”
Increased angiogenesis in the bone marrow of patients with acute myeloid leukemia
Padró, T., Ruiz, S., Bieker, R., Bürger, H., Steins, M., Kienast, J., Büchner, T., Berdel, W. E., & Mesters, R. M. (2000) · Blood · doi:10.1182/blood.v95.8.2637 · Cited by 476
Sunwoo, J. B., Chen, Z., Dong, G., Yeh, N. T., Bancroft, C. C., Sausville, E. A., Adams, J., Elliott, P. J., & Waes, C. V. (2001) · PubMed · Cited by 473
Mechanism of action of lenalidomide in hematological malignancies
Kotla, V., Goel, S., Nischal, S., Heuck, C., Vivek, K., Das, B., & Verma, A. (2009) · Journal of Hematology & Oncology · doi:10.1186/1756-8722-2-36 · Cited by 467
Fiedler, W., Graeven, U., Ergün, S., Verago, S., Kilic, N., Stockschläder, M., & Hossfeld, D. K. (1997) · Blood · doi:10.1182/blood.v89.6.1870 · Cited by 437 · cited 2×
“Apparently, this growth factor is expressed in many other leukemic cell lines [7,26] and a subset of leukemic cells also expresses VEGFR-2 which allows VEGF to act as autocrine growth factor in leukemia [26,27].”
Autocrine stimulation of VEGFR-2 activates human leukemic cell growth and migration
Dias, S., Hattori, K., Zhu, Z., Heissig, B., Choy, M., Lane, W., Wu, Y., Chadburn, A., Hyjek, E., Gill, M., et al. (2000) · Journal of Clinical Investigation · doi:10.1172/jci8978 · Cited by 434 · cited 1×
“Apparently, this growth factor is expressed in many other leukemic cell lines [7,26] and a subset of leukemic cells also expresses VEGFR-2 which allows VEGF to act as autocrine growth factor in leukemia [26,27].”
Mateos, M.-V., Richardson, P. G., Schlag, R., Khuageva, N. K., Dimopoulos, M. A., Shpilberg, O., Kropff, M., Spicka, I., Petrucci, M. T., Palumbo, A., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.0638 · Cited by 433
Podar, K., Tai, Y.-T., Davies, F. E., Lentzsch, S., Sattler, M., Hideshima, T., Lin, B. K., Gupta, D., Shima, Y., Chauhan, D., et al. (2001) · Blood · doi:10.1182/blood.v98.2.428 · Cited by 415 · cited 1×
“It has been shown that MM cells are capable of secreting VEGF in response to Interleukin-6 (IL-6) stimulation; in response to that VEGF stimulation microvascular endothelial cells and bone marrow stromal cells secrete in turn IL-6, a potent growth factor for malignant plasma cells, thus closing a paracrine loop [43].”
Jundt, F., Anagnostopoulos, I., Förster, R., Mathas, S., Stein, H., & Dörken, B. (2002) · Blood · doi:10.1182/blood.v99.9.3398 · Cited by 394 · cited 1×
“An important role of Notch has been proposed in cell survival in several B-cell malignancies such as Hodgkin's disease [31,32] and in two B-cell non-Hodgkin lymphoma entities, chronic lymphocytic leukaemia (CLL) [33-35] and in MM [36,37].”
The pathophysiologic role of VEGF in hematologic malignancies: therapeutic implications
Podar, K., & Anderson, K. C. (2005) · Blood · doi:10.1182/blood-2004-07-2909 · Cited by 343 · cited 1×
“VEGF triggered effects in MM cells are predominantly mediated via VEGFR 1 and in endothelial cells, predominantly via VEGF R2 [ 44 ].”
Kane, R. C., Farrell, A. T., Sridhara, R., & Pazdur, R. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0170 · Cited by 341 · cited 1×
“In a phase III study, patients with MM progressing after at least one prior therapy, were randomized to receive single-agent bortezomib or high-dose dexamethasone [102].”
Prognostic value of bone marrow angiogenesis in multiple myeloma.
Rajkumar, S. V., Leong, T. L., Roche, P. C., Fonseca, R., Dispenzieri, A. A., Lacy, M. Q., Lust, J. A., Witzig, T. E., Kyle, R. A., Gertz, M. A., et al. (2000) · PubMed · Cited by 338
Aguayo, A., Estey, E., Kantarjian, H., Mansouri, T., Gidel, C., Keating, M., Giles, F., Estrov, Z., Barlogie, B., & Albitar, M. (1999) · Blood · doi:10.1182/blood.v94.11.3717 · Cited by 319
Drevs, J., Siegert, P., Medinger, M., Mross, K., Strecker, R., Zirrgiebel, U., Harder, J., Blum, H., Robertson, J., Jürgensmeier, J. M., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.07.2066 · Cited by 303 · cited 1×
“In our study, cediranib was well tolerated up to 45 mg/d in patients with a broad range of solid tumors [ 81 ].”
Self-citationRosati, E., Sabatini, R., Rampino, G., Tabilio, A., Di Ianni, M., Fettucciari, K., Bartoli, A., Coaccioli, S., Screpanti, I., & Marconi, P. (2009) · Blood · doi:10.1182/blood-2008-02-139725 · Cited by 302 · cited 2×
“Patients with AML blasts expressing high levels of VEGF mRNA by quantitative polymerase chain reaction (PCR) had a significantly higher response rate and reduction of bone marrow MVD than patients with Receptor tyrosine kinase inhibitors PTK787/ZK 222584 (Vatalanib®) VEGFR1-3, PDGFRβ, c-Kit AML, PMF, MDS, CML, DLBCL,…”
Li, J.-L., Sainson, R. C. A., Shi, W., Leek, R., Harrington, L. S., Preusser, M., Biswas, S., Turley, H., Heikamp, E., Hainfellner, J. A., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-0969 · Cited by 299 · cited 1×
“Further, certain xenografts that are resistant to anti-VEGF therapy are reported to be sensitive to anti-Dll4 and combination treatment with antiVEGF and anti-Dll4 has additive inhibitory effects on tumor growth [13-15].”
Aguayo, A., Estey, E., Kantarjian, H., Mansouri, T., Gidel, C., Keating, M., Giles, F., Estrov, Z., Barlogie, B., & Albitar, M. (1999) · Blood · doi:10.1182/blood.v94.11.3717.423k09_3717_3721 · Cited by 299 · cited 2×
“In addition to that, isolated blast cells from leukemia patients also produce VEGF and the cellular level of VEGF in AML patients has been identified as independent prognostic risk factor [28].”
Dredge, K., Marriott, J. B., Macdonald, C. D., Man, H.-W., Chen, R., Muller, G. W., Stirling, D., & Dalgleish, A. G. (2002) · British Journal of Cancer · doi:10.1038/sj.bjc.6600607 · Cited by 296
The Delta paradox: DLL4 blockade leads to more tumour vessels but less tumour growth
Thurston, G., Noguera-Troise, I., & Yancopoulos, G. D. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2130 · Cited by 290 · cited 4×
“It interacts with Notch cell surface receptors to act as a negative feedback inhibitor downstream of VEGF signaling to restrain the sprouting and branching of new blood vessels [10,12].”
InfluentialRoccaro, A. M., Hideshima, T., Raje, N., Kumar, S., Ishitsuka, K., Yasui, H., Shiraishi, N., Ribatti, D., Nico, B., Vacca, A., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-1195 · Cited by 284
Kralovics, R., Teo, S.-S., Li, S., Theocharides, A., Buser, A. S., Tichelli, A., & Skoda, R. C. (2006) · Blood · doi:10.1182/blood-2005-11-009605 · Cited by 278 · cited 11×
“All together, vatalanib had modest activity in patients with PMF [79].”
InfluentialAngiogenesis in myelodysplastic syndromes
Pruneri, G., Bertolini, F., Soligo, D., Carboni, N., Cortelezzi, A., Ferrucci, P. F., Buffa, R., Lambertenghi-Deliliers, G., & Pezzella, F. (1999) · British Journal of Cancer · doi:10.1038/sj.bjc.6693515 · Cited by 271 · cited 1×
“Pathophysiology of angiogenesis in hematological malignancies Many studies suggest a role for angiogenesis not only in the pathogenesis of solid tumors but also in hematological malignancies like acute and chronic leukemia, lymphoma, myelodysplastic syndromes, myeloproliferative neoplasms, and multiple myeloma [16-21].”
Nefedova, Y., Cheng, P., Alsina, M., Dalton, W. S., & Gabrilovich, D. I. (2004) · Blood · doi:10.1182/blood-2003-07-2340 · Cited by 270 · cited 1×
“An important role of Notch has been proposed in cell survival in several B-cell malignancies such as Hodgkin's disease [31,32] and in two B-cell non-Hodgkin lymphoma entities, chronic lymphocytic leukaemia (CLL) [33-35] and in MM [36,37].”
A phase 2 clinical study of SU5416 in patients with refractory acute myeloid leukemia
Fiedler, W., Mesters, R., Tinnefeld, H., Loges, S., Staib, P., Dührsen, U., Flasshove, M., Ottmann, O. G., Jung, W., Cavalli, F., et al. (2003) · Blood · doi:10.1182/blood-2002-10-2998 · Cited by 262 · cited 5×
“SU5416 (Semaxinib) is a small molecule inhibitor of VEGFR-1 and 2, c-kit and Flt3 [70-72].”
InfluentialLenalidomide therapy in myelofibrosis with myeloid metaplasia
Tefferi, A., Cortes, J., Verstovsek, S., Mesa, R. A., Thomas, D., Lasho, T. L., Hogan, W. J., Litzow, M. R., Allred, J. B., Jones, D., et al. (2006) · Blood · doi:10.1182/blood-2006-02-004572 · Cited by 253 · cited 1×
“In phase II studies with lenalidomide monotherapy in patients with symptomatic PMF, the overall response rates were 22% for anemia, 33% for splenomegaly, and 50% for thrombocytopenia [98].”
松山, 智. (2005) · Mebio oncology · Cited by 242
Diez, H., Fischer, A., Winkler, A., Hu, C.-J., Hatzopoulos, A. K., Breier, G., & Gessler, M. (2007) · Experimental Cell Research · doi:10.1016/j.yexcr.2006.09.009 · Cited by 224 · cited 1×
“It interacts with Notch cell surface receptors to act as a negative feedback inhibitor downstream of VEGF signaling to restrain the sprouting and branching of new blood vessels [10,12].”
Drevs, J., Müller-Driver, R., Wittig, C., Fuxius, S., Esser, N., Hugenschmidt, H., Konerding, M. A., ALLEGRINI, P. R., Wood, J. M., Hennig, J., et al. (2002) · PubMed · Cited by 220
Lundberg, L. G., Lerner, R., Sundelin, P., Rogers, R., Folkman, J., & Palmblad, J. (2000) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64511-7 · Cited by 219 · cited 1×
“The available data on angiogenesis and expression of VEGF and its receptors in the bone marrow of patients with BCR-ABL1-negative myeloproliferative neoplasms (MPN) suggest that MVD is increased, especially in primary myelofibrosis (PMF), and that increased angiogenesis might inversely correlate with survival [55-58].”
Jagged1-induced Notch signaling drives proliferation of multiple myeloma cells
Jundt, F., Pröbsting, K. S., Anagnostopoulos, I., Muehlinghaus, G., Chatterjee, M., Mathas, S., Bargou, R. C., Manz, R., Stein, H., & Dörken, B. (2004) · Blood · doi:10.1182/blood-2003-07-2254 · Cited by 217 · cited 1×
“An important role of Notch has been proposed in cell survival in several B-cell malignancies such as Hodgkin's disease [31,32] and in two B-cell non-Hodgkin lymphoma entities, chronic lymphocytic leukaemia (CLL) [33-35] and in MM [36,37].”
Giles, F. J., Stopeck, A. T., Silverman, L. R., Lancet, J. E., Cooper, M. A., Hannah, A. L., Cherrington, J. M., O'Farrell, A.-M., Yuen, H. A., Louie, S. G., et al. (2003) · Blood · doi:10.1182/blood-2002-10-3023 · Cited by 200 · cited 4×
“Patients with AML blasts expressing high levels of VEGF mRNA by quantitative polymerase chain reaction (PCR) had a significantly higher response rate and reduction of bone marrow MVD than patients with Receptor tyrosine kinase inhibitors PTK787/ZK 222584 (Vatalanib®) VEGFR1-3, PDGFRβ, c-Kit AML, PMF, MDS, CML, DLBCL,…”
InfluentialProperties of thalidomide and its analogues: Implications for anticancer therapy
Teo, S. K. (2005) · The AAPS Journal · doi:10.1208/aapsj070103 · Cited by 184 · cited 1×
“The newer IMiDs were found to be 2-3 times more potent compared to thalidomide concerning anti-angiogenic activity in various in vivo assays [88].”
Karp, J. E., Gojo, I., Pili, R., Gocke, C. D., Greer, J., Guo, C., Qian, D., Morris, L., Tidwell, M., Chen, H., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0627 · Cited by 180 · cited 1×
“bevacizumab was administered after chemotherapy to adults with refractory or relapsed AML [69].”
Anderson, K. (2003) · European Journal of Haematology · doi:10.1034/j.1600-0609.2003.01067.x · Cited by 168
Expression of VEGF and its receptors by myeloma cells
Kumar, S. K., Witzig, T. E., Timm, M., Haug, J., Wellik, L. E., Fonseca, R., Greipp, P. R., & Rajkumar, S. V. (2003) · Leukemia · doi:10.1038/sj.leu.2403084 · Cited by 167 · cited 1×
“Malignant plasma cells can secrete various cytokines, including VEGF, basic fibroblast growth factor (bFGF), and hepatocyte growth factor (HGF), all known for their pro-angiogenic activity [42].”
Mross, K., Drevs, J., Müller, M., Medinger, M., Marmé, D., Hennig, J., Morgan, B., Lebwohl, D., Masson, E., Ho, Y.-Y., et al. (2005) · European Journal of Cancer · doi:10.1016/j.ejca.2005.03.005 · Cited by 165 · cited 1×
“In a phase I study by us, vatalanib was well tolerated and showed clinical activity in a variety of solid tumors [ 74 ].”
Self-citationQuintás-Cardama, A., Kantarjian, H. M., Manshouri, T., Thomas, D., Cortes, J., Ravandi, F., Garcia-Manero, G., Ferrajoli, A., Bueso-Ramos, C., & Verstovsek, S. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.22.6548 · Cited by 155 · cited 1×
“In a combination study of lenalidomide with prednisone, 40 patients with PMF were included [99].”
Casella, I., Feccia, T., Chelucci, C., Samoggia, P., Castelli, G., Guerriero, R., Parolini, I., Petrucci, E., Pelosi, E., Morsilli, O., et al. (2003) · Blood · doi:10.1182/blood-2002-07-2184 · Cited by 155 · cited 1×
“VEGFR-1 is also expressed on hematopoietic stem cells, vascular smooth muscle cells, monocytes, and leukemic cells [6,7], while VEGFR-2 is expressed on endothelial progenitor cells and megakaryocytes [8,9].”
Kumar, S., Witzig, T. E., Timm, M., Haug, J., Wellik, L., Kimlinger, T. K., Greipp, P. R., & Rajkumar, S. V. (2004) · Blood · doi:10.1182/blood-2003-11-3811 · Cited by 148 · cited 1×
“smoldering MM, and newly diagnosed MM [ 46 ], rising the hypothesis that MVD increase in plasma cell neoplasias could be rather a function of chronology.”
Aguayo, Á., Kantarjian, H. M., Estey, E. H., Giles, F. J., Verstovšek, S., Manshouri, T., Gidel, C., O'Brien, S. M., Keating, M. J., & Albitar, M. X. (2002) · Cancer · doi:10.1002/cncr.10900 · Cited by 147 · cited 1×
“Similarly, in previously untreated acute myeloid leukemia (AML), increased levels of plasma VEGF correlate with reduced survival and lower remission rates [53].”
Sezer, O., Niemöller, K., Eucker, J., Jakob, C., KAUFMANN, O. W., Zavrski, I., Dietel, M., & Possinger, K. (2000) · Annals of Hematology · doi:10.1007/s002770000236 · Cited by 147 · cited 1×
“New vessel formation in the bone marrow seems to play an important role in the pathogenesis of MM [39,40].”
Notch2 is involved in the overexpression of CD23 in B-cell chronic lymphocytic leukemia
Hubmann, R., Schwarzmeier, J. D., Shehata, M., Hilgarth, M., Duechler, M., Dettke, M., & Berger, R. (2002) · Blood · doi:10.1182/blood.v99.10.3742 · Cited by 132 · cited 2×
“Patients with AML blasts expressing high levels of VEGF mRNA by quantitative polymerase chain reaction (PCR) had a significantly higher response rate and reduction of bone marrow MVD than patients with Receptor tyrosine kinase inhibitors PTK787/ZK 222584 (Vatalanib®) VEGFR1-3, PDGFRβ, c-Kit AML, PMF, MDS, CML, DLBCL,…”
Attar, E. C., DeAngelo, D. J., Supko, J. G., D’Amato, F., Zahrieh, D., Sirulnik, A., Wadleigh, M., Ballen, K. K., McAfee, S., Miller, K. B., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4626 · Cited by 130 · cited 1×
“In a phase I study, bortezomib was added to induction chemotherapy in patients with AML [105].”
Mesters, R. M., Padró, T., Bieker, R., Steins, M. B., Kreuter, M., Göner, M., Kelsey, S. M., Scigalla, P., Fiedler, W., Büchner, T., et al. (2001) · Blood · doi:10.1182/blood.v98.1.241 · Cited by 127 · cited 4×
“Patients with AML blasts expressing high levels of VEGF mRNA by quantitative polymerase chain reaction (PCR) had a significantly higher response rate and reduction of bone marrow MVD than patients with Receptor tyrosine kinase inhibitors PTK787/ZK 222584 (Vatalanib®) VEGFR1-3, PDGFRβ, c-Kit AML, PMF, MDS, CML, DLBCL,…”
InfluentialDelta-like 4/Notch Signaling and Its Therapeutic Implications
Yan, M., & Plowman, G. D. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1393 · Cited by 121 · cited 1×
“vascular endothelial cells and induced by VEGF [11].”
Munshi, N. C., & Wilson, C. (2001) · Seminars in Oncology · doi:10.1016/s0093-7754(01)90025-9 · Cited by 119 · cited 1×
“Increased bone marrow microvessel density (MVD) in patients with MM appears to be also an important prognostic factor [41].”
Loges, S., Heil, G., Bruweleit, M., Schoder, V., Butzal, M., Fischer, U., Gehling, U. M., Schuch, G., HOSSFELD, D. K., & Fiedler, W. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.058 · Cited by 110 · cited 1×
“Thereby, the extent of angiogenesis in the bone marrow often correlated with disease burden, progonosis, and treatment outcome [22,23].”
Thalidomide therapy for myelofibrosis with myeloid metaplasia
Thomas, D. A., Giles, F. J., Albitar, M. X., Cortes, J. E., Verstovšek, S., Faderl, S. H., O'Brien, S. M., Garcia‐Manero, G., Keating, M. J., Pierce, S. A., et al. (2006) · Cancer · doi:10.1002/cncr.21827 · Cited by 101 · cited 1×
“In a phase II study with 44 PMF patients thalidomide was examined as monotherapy [94].”
Efficacy and safety of thalidomide in patients with acute myeloid leukemia
Steins, M. B., Padró, T., Bieker, R., Ruiz, S., Kropff, M. H., Kienast, J., Keßler, T., Büchner, T., Berdel, W. E., & Mesters, R. M. (2002) · Blood · doi:10.1182/blood.v99.3.834 · Cited by 95 · cited 1×
“[92] a dose-escalating trial was performed to study the safety and efficacy of thalidomide in 20 AML patients.”
Angiogenesis and antiangiogenic therapy in hematologic malignancies
Dong, X., Han, Z., & Yang, R. (2006) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2006.11.006 · Cited by 83 · cited 1×
“"Angiogenesis switch" in leukemia is documented by increased bone marrow MVD, increased expression of HIF-1, multiple pro-angiogenic factors (VEGF, bFGF, angiopoietin-2), soluble VEGFR, and decreased expression of endogenous angiogenesis inhibitors, such as thrombospondin-1 [50,51].”
Medinger, M., Skoda, R. C., Gratwohl, A. A., Theocharides, A. P. A., Buser, A. S., Heim, D. A., Dirnhofer, S., Tichelli, A., & Tzankov, A. (2009) · British Journal of Haematology · doi:10.1111/j.1365-2141.2009.07726.x · Cited by 83 · cited 3×
“We and others reported an increased microvessel density and VEGF expression in the bone marrow of patients with myeloproliferative neoplasms and lymphoma [17,20].”
Self-citationRoboz, G. J., Giles, F. J., List, A. F., Cortes, J. E., Carlin, R., Kowalski, M., Bilic, S., Masson, E., Rosamilia, M., Schuster, M. W., et al. (2006) · Leukemia · doi:10.1038/sj.leu.2404213 · Cited by 80
Zahiragic, L., Schliemann, C., Bieker, R., Thoennissen, N. H., Burow, K., Kramer, C., Zühlsdorf, M., Berdel, W. E., & Mesters, R. M. (2007) · Leukemia · doi:10.1038/sj.leu.2404632 · Cited by 80
Jundt, F., Açıkgöz, Ö., Kwon, S.-H., Schwarzer, R., Anagnostopoulos, I., Wiesner, B., Mathas, S., Hummel, M., Stein, H., Reichardt, H. M., et al. (2008) · Leukemia · doi:10.1038/leu.2008.101 · Cited by 79 · cited 1×
“An important role of Notch has been proposed in cell survival in several B-cell malignancies such as Hodgkin's disease [31,32] and in two B-cell non-Hodgkin lymphoma entities, chronic lymphocytic leukaemia (CLL) [33-35] and in MM [36,37].”
Duechler, M., Shehata, M. M., Schwarzmeier, J. D., Hoelbl‐Kovacic, A., Hilgarth, M., & Hubmann, R. (2004) · Leukemia · doi:10.1038/sj.leu.2403592 · Cited by 76 · cited 2×
“Patients with AML blasts expressing high levels of VEGF mRNA by quantitative polymerase chain reaction (PCR) had a significantly higher response rate and reduction of bone marrow MVD than patients with Receptor tyrosine kinase inhibitors PTK787/ZK 222584 (Vatalanib®) VEGFR1-3, PDGFRβ, c-Kit AML, PMF, MDS, CML, DLBCL,…”
Raza, A., Mehdi, M., Mumtaz, M. A., Ali, F., Lascher, S., & Galili, N. (2008) · Cancer · doi:10.1002/cncr.23789 · Cited by 70 · cited 1×
“A combination therapy of thalidomide and 5-azacytidine, a hypomethylating drug, was examined in 40 patients with MDS and AML [ 93 ].”
Angiogenesis in nodal B cell lymphomas: a high throughput study
Tzankov, A., Heiss, S., Ebner, S., Sterlacci, W., Schaefer, G., Augustin, F., Fiegl, M., & Dirnhofer, S. (2006) · Journal of Clinical Pathology · doi:10.1136/jcp.2006.038661 · Cited by 64 · cited 2×
“We and others reported an increased microvessel density and VEGF expression in the bone marrow of patients with myeloproliferative neoplasms and lymphoma [17,20].”
Frater, J. L., Kay, N. E., Goolsby, C. L., Crawford, S. E., Dewald, G. W., & Peterson, L. C. (2008) · Diagnostic Pathology · doi:10.1186/1746-1596-3-16 · Cited by 56 · cited 1×
“"Angiogenesis switch" in leukemia is documented by increased bone marrow MVD, increased expression of HIF-1, multiple pro-angiogenic factors (VEGF, bFGF, angiopoietin-2), soluble VEGFR, and decreased expression of endogenous angiogenesis inhibitors, such as thrombospondin-1 [50,51].”
Gianelli, U., Vener, C., Raviele, P. R., Savi, F., Somalvico, F., Calori, R., Iurlo, A., Radaelli, F., Fermo, E., Bucciarelli, P., et al. (2007) · American Journal of Clinical Pathology · doi:10.1309/fp0n3lc8mbjuffa6 · Cited by 56
Yetgin, S., Yenicesu, İ., Icletin, M., & Tuncer, M. A. (2001) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428190109097679 · Cited by 52 · cited 1×
“Moreover, it was also shown that urine and peripheral blood samples from ALL patients contained elevated levels of pro-angiogenic growth factors, namely bFGF and VEGF, which correlated with the increase of bone marrow angiogenesis [48].”
Thalidomide--effect on T cell subsets as a possible mechanism of action.
Moncada, B., Ml, B., González‐Amaro, R., Urbina, R., & Ce, L. (1985) · PubMed · Cited by 45
Alonci, A., Allegra, A., Bellomo, G., Penna, G., D’Angelo, A., Quartarone, E., & Musolino, C. (2008) · Hematological Oncology · doi:10.1002/hon.865 · Cited by 43 · cited 10×
“All together, vatalanib had modest activity in patients with PMF [79].”
InfluentialAn open-label, Phase I study of cediranib (RECENTIN™) in patients with acute myeloid leukemia
Fiedler, W., Mesters, R. M., Heuser, M., Ehninger, G., Berdel, W. E., Zirrgiebel, U., Robertson, J. D., Puchalski, T. A., Collins, B., Jürgensmeier, J. M., et al. (2009) · Leukemia Research · doi:10.1016/j.leukres.2009.07.020 · Cited by 41
A Review of Angiogenesis and Anti-Angiogenic Therapy in Hematologic Malignancies
Rajkumar, S. V., Mesa, R. A., & Tefferi, A. (2002) · Stem Cells and Development · doi:10.1089/152581602753448522 · Cited by 40 · cited 1×
“Rajkumar et al. showed a gradual increase of bone marrow angiogenesis along the disease spectrum from monoclonal gammopathy of undetermined significance (MGUS) to smoldering MM, newly diagnosed MM and relapsed MM [ 45 ], though the expression levels of VEGF, bFGF, and their receptors were similar among MGUS,”
Single agent thalidomide in patients with relapsed or refractory acute myeloid leukaemia
Thomas, D. A., Estey, E. H., Giles, F. J., Faderl, S. H., Cortes, J. E., Keating, M. J., O'Brien, S. M., Albitar, M. X., & Kantarjian, H. M. (2003) · British Journal of Haematology · doi:10.1046/j.1365-2141.2003.04639.x · Cited by 38 · cited 1×
“[91] thalidomide was analyzed in patients with relapsed or refractory AML previously treated with cytarabine-containing regimens.”
Wróbel, T., Mazur, G. J., Surowiak, P., Wołowiec, D., Jeleń, M., & Kuliczkowski, K. (2003) · Pathology & Oncology Research · doi:10.1007/bf03033732 · Cited by 29 · cited 1×
“The available data on angiogenesis and expression of VEGF and its receptors in the bone marrow of patients with BCR-ABL1-negative myeloproliferative neoplasms (MPN) suggest that MVD is increased, especially in primary myelofibrosis (PMF), and that increased angiogenesis might inversely correlate with survival [55-58].”
Giles, F. J., List, A. F., Carroll, M. P., Cortes, J. E., Valickas, J., Chen, B.-L., Masson, E., Jacques, C. J., Laurent, D., Albitar, M. X., et al. (2007) · Leukemia Research · doi:10.1016/j.leukres.2006.12.001 · Cited by 27 · cited 1×
“All together, vatalanib had modest activity in patients with PMF [ 79 ].”
The role of angiogenesis in the biology and therapy of myelodysplastic syndromes.
Aguayo, Á. (2004) · PubMed · Cited by 26
Ponzoni, M., Savage, D. G., Ferreri, A. J. M., Pruneri, G., Viale, G., Servida, P., Bertolini, F., & Orazi, A. (2004) · Modern Pathology · doi:10.1038/modpathol.3800224 · Cited by 23 · cited 1×
“The available data on angiogenesis and expression of VEGF and its receptors in the bone marrow of patients with BCR-ABL1-negative myeloproliferative neoplasms (MPN) suggest that MVD is increased, especially in primary myelofibrosis (PMF), and that increased angiogenesis might inversely correlate with survival [55-58].”
Norén‐Nyström, U., Heyman, M. M., Frisk, P., Golovleva, I., Sundström, C., Porwit‐MacDonald, A., Roos, G., Bergh, A. R. J., & Forestier, E. (2009) · British Journal of Haematology · doi:10.1111/j.1365-2141.2009.07796.x · Cited by 22 · cited 1×
“[52] MVD, analyzed on 185 bone marrow biopsies, was higher in TALL compared to B-ALL.”
Hou, H., Shih, T. T., Liu, C.-Y., Chen, B., Tang, J., Yao, M., Huang, S., Chou, W., Hsu, C., & Tien, H. (2010) · Haematologica · doi:10.3324/haematol.2009.019364 · Cited by 18
Barbarroja, N., Torres, L. A., Luque, M. J., Carretero, R. M., Valverde, A. M., Lopez-Sanchez, L. M., Rodríguez‐Ariza, A., Velasco, F., Torres, A., & López-Pedrera, C. (2009) · Experimental Hematology · doi:10.1016/j.exphem.2009.03.001 · Cited by 14 · cited 1×
“In a recently study by Barbarroja et al. [ 78 ] vatalanib was examined in combination with idarubicin in 4 AML cell lines and 7 AML patients samples.”
The Early Rad Catches the Tumor?
Machtay, M. X. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.20.14.3045 · Cited by 3
Research works printed but not linked: 1
- Roccaro AM Hideshima T Raje N Kumar S Ishitsuka K Yasui H Shiraishi N Ribatti D Nico B Vacca A Dammacco F Richardson PG Anderson KC Bortezomib mediates antiangiogenesis in multiple myeloma via direct and indirect effects on endothelial cells Cancer Research 2006 66 184 191 10.1158/0008-5472.CAN-05-1195 16397231 · DOI · Paper page
Cited by
Tumor microenvironment signaling and therapeutics in cancer progression
Goenka, A., Khan, F., Verma, B., Sinha, P., Dmello, C. C., Jogalekar, M. P., Gangadaran, P., & Ahn, B. (2023) · Cancer Communications · doi:10.1002/cac2.12416 · Cited by 323
“ECs are targeted indirectly for tumor therapy by inhibiting angiogenesis via neutralizing antibodies for VEGF or inhibitors of VEGF activity [34].”
BackgroundDogra, P., Adolphi, N. L., Wang, Z., Lin, Y.-S., Butler, K. S., Durfee, P. N., Croissant, J. G., Noureddine, A., Coker, E. N., Bearer, E. L., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-06730-z · Cited by 257
Endothelial Cells in the Tumor Microenvironment
Sobierajska, K., Ciszewski, W. M., Sacewicz-Hofman, I., & Niewiarowska, J. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-37184-5_6 · Cited by 179
Nanomedicines for the treatment of hematological malignancies
Deshantri, A. K., Varela-Moreira, A., Ecker, V., Mandhane, S. N., Schiffelers, R. M., Buchner, M., & Fens, M. H. A. M. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2018.08.034 · Cited by 160
Histone deacetylase inhibitors: potential targets responsible for their anti-cancer effect
Dickinson, M., Johnstone, R. W., & Prince, H. M. (2010) · Investigational New Drugs · doi:10.1007/s10637-010-9596-y · Cited by 144
“[177, 179–186].”
Metadata
- Authors
- Medinger, M., & Mross, K.
- Affiliations
- University of Freiburg (DE)
- Corresponding author
- Mross, Klaus
- ORCID
- Medinger, Michael
- Venue
- Journal of Angiogenesis Research
- Publisher
- Publiverse Online SRL
- Published
- 2010
- Volume
- 2
- Issue
- 1
- Pages
- 10
- ISSN
- 2040-2384 (ISSN-L)
- PMC
- PMC2902424
- OpenAlex
- W1987797098
- Cited by
- 40
- References
- 106
- Citations by year
- 2026: 1 · 2024: 3 · 2023: 1 · 2020: 5 · 2019: 2 · 2018: 3 · 2017: 4 · 2016: 4 · 2015: 2 · 2014: 7 · 2012: 1
- FWCI
- 0.91
- Type
- journal article
- Language
- en
- Open access
- diamond
- doi.org
- Licence
- cc-by
- Locations
- Vascular Cell (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
- Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
- Health Sciences › Medicine › Oncology › Vascular Tumors and Angiosarcomas
- Keywords
- angiogenesis, angiogenesis inhibitors, hematologic malignancies, multiple myeloma, acute leukemia, myeloproliferative neoplasms, monoclonal antibodies, receptor tyrosine kinase inhibitors, immunomodulators, proteasome inhibitors, clinical trials
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.